AR119318A1 - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1Info
- Publication number
- AR119318A1 AR119318A1 ARP200101853A ARP200101853A AR119318A1 AR 119318 A1 AR119318 A1 AR 119318A1 AR P200101853 A ARP200101853 A AR P200101853A AR P200101853 A ARP200101853 A AR P200101853A AR 119318 A1 AR119318 A1 AR 119318A1
- Authority
- AR
- Argentina
- Prior art keywords
- modulator
- positive
- allesteric
- methyl
- tetrahydroisoquinoline derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119318A1 true AR119318A1 (es) | 2021-12-09 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101853A AR119318A1 (es) | 2019-07-01 | 2020-06-30 | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12643877B2 (enExample) |
| EP (1) | EP3993794A1 (enExample) |
| JP (1) | JP7510444B2 (enExample) |
| KR (1) | KR20220029686A (enExample) |
| CN (2) | CN117700395A (enExample) |
| AR (1) | AR119318A1 (enExample) |
| AU (1) | AU2020299953B2 (enExample) |
| BR (1) | BR112021022378A2 (enExample) |
| CA (1) | CA3139571A1 (enExample) |
| CL (1) | CL2021002946A1 (enExample) |
| CO (1) | CO2021018155A2 (enExample) |
| EC (1) | ECSP21093559A (enExample) |
| IL (2) | IL319939A (enExample) |
| MA (1) | MA56440A (enExample) |
| MX (2) | MX2021015873A (enExample) |
| MY (1) | MY210361A (enExample) |
| PE (1) | PE20221020A1 (enExample) |
| PH (1) | PH12021552825A1 (enExample) |
| SA (1) | SA521431279B1 (enExample) |
| SG (1) | SG11202112537YA (enExample) |
| TW (1) | TWI875776B (enExample) |
| WO (1) | WO2021001288A1 (enExample) |
| ZA (1) | ZA202109193B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| EP4200280B1 (en) | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| SI4263517T1 (sl) | 2020-12-18 | 2025-01-31 | UCB Biopharma SRL | Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1 |
| CN116685308A (zh) | 2020-12-18 | 2023-09-01 | Ucb生物制药有限责任公司 | 无定形固体分散体 |
| ES3004257T3 (en) | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| CN117337173A (zh) * | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
| WO2026022198A1 (en) | 2024-07-25 | 2026-01-29 | UCB Biopharma SRL | Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520217A (ja) * | 2007-03-01 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物 |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| EA035544B1 (ru) | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 PH PH1/2021/552825A patent/PH12021552825A1/en unknown
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 JP JP2021577411A patent/JP7510444B2/ja active Active
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 US US17/621,851 patent/US12643877B2/en active Active
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 MY MYPI2021006862A patent/MY210361A/en unknown
- 2020-06-29 MA MA056440A patent/MA56440A/fr unknown
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/pt unknown
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/zh active Pending
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/zh active Active
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/es unknown
- 2020-06-29 AU AU2020299953A patent/AU2020299953B2/en active Active
- 2020-06-29 IL IL319939A patent/IL319939A/en unknown
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/es unknown
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en not_active Ceased
- 2020-06-29 IL IL289314A patent/IL289314B2/en unknown
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/ko active Pending
- 2020-06-30 AR ARP200101853A patent/AR119318A1/es unknown
- 2020-06-30 TW TW109122035A patent/TWI875776B/zh active
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/es unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-16 MX MX2024015493A patent/MX2024015493A/es unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/es unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/es unknown
- 2021-12-30 SA SA521431279A patent/SA521431279B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| CL2023001369A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| ECSP21093559A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| UY40282A (es) | Compuestos amido-heteroaromáticos | |
| AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| MX2025009605A (es) | Sal de derivado de anillo heteroaromatico de benzo-nitrogeno, forma cristalina y uso farmaceutico de la misma | |
| MX2023011518A (es) | Compuestos heterocíclicos novedosos y sus usos. | |
| PE20240632A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1 | |
| MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. | |
| AR133286A1 (es) | Inhibidores ra2s heterocíclicos de igf-1r para el tratamiento de enfermedades | |
| BR112019006937A2 (pt) | Composição farmacêutica, composto, forma cristalina do composto, agentes para reduzir sulfato de indoxila no sangue, para prevenir ou tratar uma doença causada por um aumento de sulfato de indoxila no sangue, para retardar a transição para terapia desubstituição renal e para suprimir o agravamento da função renal remanescente em um paciente após transição para terapia de substituição renal, uso do composto, e, métodos para reduzir sulfato de indoxila no sangue e para prevenir ou tratar uma doença | |
| UY39688A (es) | Moduladores Alostéricos Negativos Novedosos de Ciclopenta[c]pirrol de NR2B | |
| CO2025003737A2 (es) | Inhibidores de quinasa dependiente de ciclina 7 | |
| EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
| AR117270A1 (es) | 3,3-difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que comprenden lo mismo |